The Rotavirus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Rotavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rotavirus Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued products.

GlobalData tracks 29 drugs in development for Rotavirus Infections by 26 companies/universities/institutes. The top development phase for Rotavirus Infections is preclinical with eight drugs in that stage. The Rotavirus Infections pipeline has 21 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Rotavirus Infections pipeline products market are: International Vaccine Institute, MAXVAX Biotechnology and Chongqing Zhifei Biological Products.

The key targets in the Rotavirus Infections pipeline products market include VP6 Antigen.

The key mechanisms of action in the Rotavirus Infections pipeline product include VP6 Antigen Inhibitor with one drug in Discovery. The Rotavirus Infections pipeline products include five routes of administration with the top ROA being Oral and nine key molecule types in the Rotavirus Infections pipeline products market including Live Attenuated Vaccine, and Subunit Vaccine.

Rotavirus Infections overview

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus be contracted from inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms include severe diarrhea, vomiting, fever, and dehydration.

For a complete picture of Rotavirus Infections’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.